标题

板块

摘要号/作者

芦比替定联合伊立替康的Ⅱ期扩展队列中，滑膜肉瘤的疗效和安全性

Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS)

壁报

【11560】

Gregory Cote

一项芦比替定联合多柔比星对比多柔比星单药一线治疗转移性平滑肌肉瘤的随机对照、开放标签、Ⅱb/Ⅲ期临床研究

Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma

壁报

【TPS11590】

Gregory Cote

芦比替定联合或不联合阿维鲁单抗治疗膀胱小细胞癌的Ⅱ期临床研究（LASER）

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER)

壁报

【TPS4629 】

Nicholas Simon

芦比替定联合伊立替康治疗复发SCLC的Ⅱ期扩展队列结果

Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.

壁报

【8094】

Luis Paz-Ares

芦比替定对比铂再挑战治疗复发广泛期小细胞肺癌：一项回顾性队列研究

Lurbinectedin versus platinum rechallenge in relapsed extensive stage small cell lung cancer: A retrospective cohort study.

线上发表

【e20110】

Michael Libre

芦比替定在真实世界中治疗SCLC的安全性和医疗资源使用：Jazz EMERGE 402数据更新

Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.

线上发表

【8094】

Firas Badin